Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 7/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7472771 | 0.80 | DRD4 (0.60) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4321704 | 0.80 | DRD4 (0.68) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9228792 | 0.79 | SLC6A2 (0.50) | HRH3DRD4SLC6A2CYP1A2CYP3A4 | |
| SCHEMBL608360 | 0.79 | SIGMAR1 (0.66) | MC4RDRD4SIGMAR1HTR1AADRA2A | |
| SCHEMBL13887867 | 0.78 | SLC6A2 (0.42) | HRH3SLC6A2 | |
| SCHEMBL13887879 | 0.78 | SLC6A2 (0.42) | HRH3SLC6A2 | |
| Hydrochloric Acid SCHEMBL10981595 | 0.78 | SLC6A2 (0.49) | HRH3DRD4SLC6A2CYP1A2CYP3A4 | |
| SCHEMBL3017254 | 0.77 | DRD4 (0.63) | DRD4SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10202235 | 0.77 | MC4R (0.62) | MC4RDRD4SIGMAR1HTR1ADRD2 | |
| SCHEMBL31328422 | 0.76 | DRD4 (0.61) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155689-B1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2015-07-08 | — | — | EP | disclosed |
| EP-2155689-B1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2015-07-08 | — | — | EP | disclosed |
| US-8653262-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653262-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653262-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2155689-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008145681-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008145681-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | CCR2, CCRL2, CCR1 | MC4R 322/4885HRH3 222/4885DRD4 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.